LGC (Cambridge, UK) has developed a COVID-19 antibody assay that can analyze up to 40,000 samples daily and is suitable for…
Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
A study undertaken in South Korea has shown that the viral load in asymptomatic COVID-19 patients is the same as in those who show symptoms of the disease and this could be contributing to the spread of the infection in populations.
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
In collaboration with the University of Southampton, Synairgen (both Southampton, UK) have announced positive results from their recent trial of SNG001, a novel protein based COVID-19 drug.